Interleukin-12 gene transfer results in CD8-dependent regression of murine CT26 liver tumors

Annals of Surgical Oncology

Volumn 6, Issue 2, 1999, Pages 186-194

  Weber, Sharon M ^a   Shi, Fushun ^a   Heise, Charles ^a   Warner, Thomas ^a   Mahvi, David M ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b University of Wisconsin Health   (United States)

Author keywords

Cancer gene therapy; Hepatic tumors; Immunotherapy

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; LUCIFERASE; LYMPHOCYTE ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CONTROLLED STUDY; DNA TRANSFECTION; DOSE TIME EFFECT RELATION; DRUG MECHANISM; EXPERIMENTAL NEOPLASM; GENE THERAPY; HISTOPATHOLOGY; IMMUNOLOGICAL MEMORY; IMMUNOSTIMULATION; INTRATUMORAL DRUG ADMINISTRATION; LIVER CANCER; MOUSE; NONHUMAN; PROTEIN DETERMINATION; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME;

EID: 0032943223     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10434-999-0186-1     Document Type: Article

References (35)

1. Dreben JA, Niederhuber JE. Cancer of the lower gastrointestinal tract. In: Niederhuber JE, ed. Current therapy in oncology. St. Louis: Decker, 1993;426-31.
2. Steele G, Ravikumar TS. Resection of hepatic metastases from colorectal cancer: biologic perspectives. Ann Surg 1989;210:127-38.
3. Steele G Jr, Bleday R, Mayer RJ, Lindblad A, Petrelli N, Weaver D. A prospective evaluation of hepatic resection for colorectal carcinoma metastases to the liver: Gastrointestinal Tumor Study Group Protocol 6584. J Clin Oncol 1991;9:1105-12.
4. Scheele J, Stangl R, Altendorf-Hofmann A. Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg 1990;77:1241-6.
5. Marcel T, Grausz JD. The TMC Worldwide Gene Therapy Enrollment Report, end 1996. Hum Gene Ther 1997;8:775-800.
6. Wolf SF, Temple PA, Kobayashi M, et al. Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. J Immunol 1991;146:3074-81.
7. Kobayashi M, Fitz L, Ryan M, et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects. J Exp Med 1989;170:827-45.
8. 1-type responses in human Leishmania donovani infections. J Immunol 1995;154:4623-9.
9. Chan SH, Kobayashi M, Shantoli D, Perussia B, Trinchieri G. Mechanisms of IFN-gamma induction by natural killer cell stimulatory factor: role of transcription and mRNA stability in the synergistic interaction between NKSF and IL-2. J Immunol 1992; 148:92-8.
10. Tsung K, Meko JB, Peplinski GR, Tsung YL, Norton JA. IL-12 induces T helper 1-directed antitumor response. J Immunol 1997; 58:3359-65.
11. Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ, Folkman J. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 1995;87:581-6.
12. Sgadari C, Angiolillo AL, Tosato G. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood 1996;87:3877-82.
13. Tannenbaum CS, Wicker N, Armstrong D, et al. Cytokine and chemokine expression in tumors of mice receiving systemic therapy with IL-12. J Immunol 1996;156:693-9.
14. Orange JS, Salazar-Mather TP, Opal SM, et al. Mechanism of interleukin 12-mediated toxicities during experimental viral infection: role of tumor necrosis factor and glucocorticoids. J Exp Med 1995;181:901-14.
15. Marshall E. Cancer trial of interleukin-12 halted. Science 1995; 268:1555.
16. Jenks S. After initial setback, IL-12 regaining popularity. J Natl Cancer Inst 1996;88:576-77.
17. Rakhmilevich AL, Turner J, Ford MJ, et al. Gene gun-mediated skin transfection with interleukin 12 gene results in regression of established primary and metastatic murine tumors. Proc Natl Acad Sci USA 1996;93:6291-96.
18. Caruso M, Pham-Nguyen K, Kwon Y-L, et al. Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma. Proc Natl Acad Sci USA 1996;93:11302-6.
19. Armstrong CA, Botella R, Galloway TH, et al. Antitumor effects of granulocyte-macrophage colony stimulating factor production by melanoma cells. Cancer Res 1996;56:2191-8.
20. Lee C-T, Wu SH, Ciernik IF, et al. Genetic immunotherapy of established tumors with adenovirus-murine granulocyte-macrophage colony stimulating factor. Hum Gene Ther 1997;8:187-93.
21. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony stimulating factor stimulates potent, specific, and long lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993;90: 3539-43.
22. Levitsky HI, Lazenby A, Hayashi RJ, Pardoll DM. In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression. J Exp Med 1994;179:1215-24.
23. Yang NS, Sun W. Gene gun and other non-viral approaches for cancer gene therapy. Nat Med 1995;1:481-3.
24. Yang NS, Burkholder J, Roberts B, Martinell B, McCabe D. In vivo and in vitro gene transfer to mammalian somatic cells by particle bombardment. Proc Natl Acad Sci USA 1990;87:9568-72.
25. Cheng L, Ziegelhoffer PR, Yang N-S. In vivo promoter activity and transgene expression in mammalian somatic tissues evaluated by using particle bombardment. Proc Natl Acad Sci USA 1993;90: 4455-9.
26. Cheng L, Ziegelhoffer P, Yang NS. In vivo promoter activity and transgene expression in mammalian somatic tissues evaluated by using particle bombardment. Proc Natl Acad Sci USA 1993;90: 4455-9.
27. Mahvi DM, Burkholder JK, Turner J, et al. Particle-mediated gene transfer of granulocyte-macrophage colony-stimulating factor cDNA to tumor cells: implications for a clinically relevant tumor vaccine. Hum Gene Ther 1996;7:1535-43.
28. Nastala CL, Edington HD, McKinney TG, et al. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J Immunol 1994;153:1697-1706.
29. Coughlin SM, Wysocka M, Kurzawa HL, Lee WM, Trinchieri G. Eck SL. B7-1 and interleukin 12 synergistically induce effective antitumor immunity. Cancer Res 1995;55:4980-7.
30. Tahara H, Zitvogel L, Storkus WJ, et al. Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J Immunol 1995;154:6466-74.
31. Rakhmilevich AL, Janssen K, Turner J, Gulp J, Yang NS. Cytokine gene therapy of cancer using gene gun technology: superior antitumor activity of interleukin-12. Hum Gene Ther 1997;8:1303-11.
32. Brunda MJ, Luistro L, Warrier RR, et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 1993;178:1223-30.
33. + αβ T cells with intermediate TCR induced in the liver of mice by IL-12. J Immunol 1995;154:4333-40.
34. Rao JB, Chamberlain RS, Bronte V, et al. IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines. J Immunol 1996;156:3357-65.
35. Cui J, Shin T, Kawano T, et al. Requirement for Vα14 NKT cells in IL-12-mediated rejection of tumors. Science 1997;278:1623-6.